Sang-Hak Lee

List of Publications by Year
in descending order

104	1,924	318942	355658
papers	citations	23	38
		h-index	g-index

112	112	112	4267
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genetic Variants Associated with Supernormal Coronary Arteries. Journal of Atherosclerosis and Thrombosis, 2023, 30, 467-480.	0.9	4
2	Prevalence and prognosis of refractory hypertension diagnosed using ambulatory blood pressure measurements. Hypertension Research, 2022, 45, 1353-1362.	1.5	5
3	Genetic Variants Associated with Adverse Events after Angiotensin-Converting Enzyme Inhibitor Use: Replication after GWAS-Based Discovery. Yonsei Medical Journal, 2022, 63, 342.	0.9	2
4	Cardiovascular Risk and Treatment Outcomes in Severe Hypercholesterolemia: A Nationwide Cohort Study. Journal of the American Heart Association, 2022, 11, e024379.	1.6	6
5	Phenotypic and Genetic Analyses of Korean Patients with Familial Hypercholesterolemia: Results from the KFH Registry 2020. Journal of Atherosclerosis and Thrombosis, 2021, , .	0.9	5
6	Role of Genetics in Preventive Cardiology: Focused on Dyslipidemia. Korean Circulation Journal, 2021, 51, 899.	0.7	4
7	Nlrp3, Csf3, and Edn1 in Macrophage Response to Saturated Fatty Acids and Modified Low-Density Lipoprotein. Korean Circulation Journal, 2021, 51, 68.	0.7	3
8	Statin Therapy in HIGH-Risk Individuals with NORMal Coronary Arteries: The HIGH-NORM Study. Journal of Atherosclerosis and Thrombosis, 2021, , .	0.9	1
9	Cholesterol Efflux and Collateral Circulation in Chronic Total Coronary Occlusion: Effect‑Circ Study. Journal of the American Heart Association, 2021, 10, e019060.	1.6	6
10	Escalation of liPid-lOwering therapy in patientS wiTh vascular disease receiving HIGH-intensity statins: the retrospective POST-HIGH study. Scientific Reports, 2021, 11, 8884.	1.6	1
11	Common and differential effects of docosahexaenoic acid and eicosapentaenoic acid on helper T-cell responses and associated pathways. BMB Reports, 2021, 54, 278-283.	1.1	6
12	Deep-learning-based cardiovascular risk stratification using coronary artery calcium scores predicted from retinal photographs. The Lancet Digital Health, 2021, 3, e306-e316.	5.9	93
13	Purine metabolite-based machine learning models for risk prediction, prognosis, and diagnosis of coronary artery disease. Biomedicine and Pharmacotherapy, 2021, 139, 111621.	2.5	9
14	Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis. Scientific Reports, 2021, 11, 16335.	1.6	12
15	Association of muscular fitness with rehospitalization for heart failure with reduced ejection fraction. Clinical Cardiology, 2021, 44, 244-251.	0.7	8
16	Relationship between Retinal nerve Fiber Layer Defects and Coronary Artery Calcium Score in Patients at Risk for Cardiovascular Disease. Cardiovascular Prevention and Pharmacotherapy, 2021, 3, 95.	0.0	0
17	Comparison of the Association Between Arterial Stiffness Indices and Heart Failure in Patients With High Cardiovascular Risk: A Retrospective Study. Frontiers in Cardiovascular Medicine, 2021, 8, 782849.	1.1	5
18	LncRNA HSPA7 in human atherosclerotic plaques sponges miR-223 and promotes the proinflammatory vascular smooth muscle cell transition. Experimental and Molecular Medicine, 2021, 53, 1842-1849.	3.2	6

#	ARTICLE	IF	CITATIONS
19	Optimal Low-Density Lipoprotein Cholesterol Levels in Adults Without Diabetes Mellitus: A Nationwide Population-Based Study Including More Than 4 Million Individuals From South Korea. Frontiers in Cardiovascular Medicine, 2021, 8, 812416.	1.1	3
20	Clinical impact of guideline-based practice and patients' adherence in uncontrolled hypertension. Clinical Hypertension, 2021, 27, 26.	0.7	3
21	Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9. European Heart Journal, 2020, 41, 239-252.	1.0	61
22	Atorvastatin protects cardiomyocyte from doxorubicin toxicity by modulating survivin expression through FOXO1 inhibition. Journal of Molecular and Cellular Cardiology, 2020, 138, 244-255.	0.9	26
23	GENetic characteristics and REsponse to lipid-lowering therapy in familial hypercholesterolemia: GENRE-FH study. Scientific Reports, 2020, 10, 19336.	1.6	9
24	Anti-Inflammatory Actions of Soluble Ninjurin-1 Ameliorate Atherosclerosis. Circulation, 2020, 142, 1736-1751.	1.6	34
25	Prevalence and prognosis of the 2018 vs 2008 AHA definitions of apparent treatment‐resistant hypertension in high‐risk hypertension patients. Journal of Clinical Hypertension, 2020, 22, 2093-2102.	1.0	11
26	Increased aortic augmentation index is associated with reduced exercise capacity after heart transplantation. Journal of Hypertension, 2020, 38, 1777-1785.	0.3	1
27	Differential contributions of sarcomere and mitochondria-related multigene variants to the endophenotype of hypertrophic cardiomyopathy. Mitochondrion, 2020, 53, 48-56.	1.6	8
28	Oxidized LDL induces vimentin secretion by macrophages and contributes to atherosclerotic inflammation. Journal of Molecular Medicine, 2020, 98, 973-983.	1.7	27
29	Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease. ESC Heart Failure, 2020, 7, 1125-1129.	1.4	46
30	Effects of Statins for Primary Prevention in the Elderly: Recent Evidence. Journal of Lipid and Atherosclerosis, 2020, 9, 1.	1.1	3
31	We can do much better than what we did. Korean Journal of Internal Medicine, 2020, 35, 547-549.	0.7	1
32	Effect of FIXed-dose combination of ARb and statin on adherence and risk factor control: The randomized FIXAR study. Cardiology Journal, 2020, , .	0.5	6
33	Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin. Journal of Lipid and Atherosclerosis, 2020, 9, 283.	1.1	2
34	Novel Associations between Related Proteins and Cellular Effects of High-Density Lipoprotein. Korean Circulation Journal, 2020, 50, 236.	0.7	1
35	CETP, LIPC, and SCARB1 variants in individuals with extremely high high-density lipoprotein-cholesterol levels. Scientific Reports, 2019, 9, 10915.	1.6	11
36	2018 Guidelines for the Management of Dyslipidemia in Korea. Journal of Lipid and Atherosclerosis, 2019, 8, 78.	1.1	100

#	Article	IF	Citations
37	PRavastatin Versus FlUVastatin After Statin Intolerance: The PRUV-Intolerance Study With Propensity Score Matching. American Journal of Medicine, 2019, 132, 1320-1326.e1.	0.6	4
38	Synergistic protective effects of a statin and an angiotensin receptor blocker for initiation and progression of atherosclerosis. PLoS ONE, 2019, 14, e0215604.	1.1	12
39	Statin and clinical outcomes of primary prevention in individuals aged >75 years: The SCOPE-75 study. Atherosclerosis, 2019, 284, 31-36.	0.4	27
40	2018 Guidelines for the management of dyslipidemia. Korean Journal of Internal Medicine, 2019, 34, 723-771.	0.7	144
41	Dyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in Korea. Journal of Lipid and Atherosclerosis, 2019, 8, 242.	1.1	10
42	Effect of Niacin on Carotid Atherosclerosis in Patients at Low-Density Lipoprotein-Cholesterol Goal but High Lipoprotein (a) Level: a 2-Year Follow-Up Study. Journal of Lipid and Atherosclerosis, 2019, 8, 58.	1.1	3
43	Characteristics of Acute Cerebral Infarction in Patients with Familial Hypercholesterolemia. Journal of the Korean Neurological Association, 2019, 37, 361-367.	0.0	0
44	Novel association between CDKAL1 and cholesterol efflux capacity: Replication after GWAS-based discovery. Atherosclerosis, 2018, 273, 21-27.	0.4	5
45	GAREM1 regulates the PR interval on electrocardiograms. Journal of Human Genetics, 2018, 63, 297-307.	1.1	2
46	Metabolic phenotyping of human atherosclerotic plaques: Metabolic alterations and their biological relevance in plaque-containing aorta. Atherosclerosis, 2018, 269, 21-28.	0.4	21
47	Atherogenic dyslipidemia promotes autoimmune follicular helper T cell responses via IL-27. Nature Immunology, 2018, 19, 583-593.	7.0	60
48	Prdx1 (peroxiredoxin 1) deficiency reduces cholesterol efflux via impaired macrophage lipophagic flux. Autophagy, 2018, 14, 120-133.	4.3	62
49	The Association between Social Network Betweenness and Coronary Calcium: A Baseline Study of Patients with a High Risk of Cardiovascular Disease. Journal of Atherosclerosis and Thrombosis, 2018, 25, 131-141.	0.9	6
50	Screening, Diagnosis, and Treatment of Familial Hypercholesterolemia: Symposium of the Education Committee, Korean Society of Lipid and Atherosclerosis. Journal of Lipid and Atherosclerosis, 2018, 7, 122.	1.1	2
51	Effect of fenofibrate in 1113 patients at low-density lipoprotein cholesterol goal but high triglyceride levels: Real-world results and factors associated with triglyceride reduction. PLoS ONE, 2018, 13, e0205006.	1.1	7
52	Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin. Scientific Reports, 2018, 8, 14642.	1.6	5
53	Analysis of lipoprotein-specific lipids in patients with acute coronary syndrome by asymmetrical flow field-flow fractionation and nanoflow liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1099, 56-63.	1.2	20
54	Variants of Lipolysis-Related Genes in Korean Patients with Very High Triglycerides. Yonsei Medical Journal, 2018, 59, 148.	0.9	8

#	Article	IF	Citations
55	Optimal Blood Pressure in Elderly Hypertensive Subjects: A Korean National Health Insurance Service Health Examinee Cohort Study. American Journal of Hypertension, 2018, 31, 1033-1041.	1.0	3
56	C1q/TNF-Î±â€"Related Protein 1 (CTRP1) Maintains Blood Pressure Under Dehydration Conditions. Circulation Research, 2018, 123, e5-e19.	2.0	21
57	Palmitate and minimally-modified low-density lipoprotein cooperatively promote inflammatory responses in macrophages. PLoS ONE, 2018, 13, e0193649.	1.1	9
58	Macrophage polarization and acceleration of atherosclerotic plaques in a swine model. PLoS ONE, 2018, 13, e0193005.	1.1	18
59	Association of Morning Hypertension Subtype With Vascular Target Organ Damage and Central Hemodynamics. Journal of the American Heart Association, 2017, 6, .	1.6	9
60	Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk. Clinical Therapeutics, 2017, 39, 107-117.	1.1	37
61	Target achievement with maximal statinâ€"based lipidâ€"lowering therapy in Korean patients with familial hypercholesterolemia: A study supported by the Korean Society of Lipid and Atherosclerosis. Clinical Cardiology, 2017, 40, 1291-1296.	0.7	10
62	Relation Between Blood Pressure and Clinical Outcome in Hypertensive Subjects With Previous Stroke. Journal of the American Heart Association, 2017, 6, .	1.6	6
63	Effect of two lipid-lowering strategies on high-density lipoprotein function and some HDL-related proteins: a randomized clinical trial. Lipids in Health and Disease, 2017, 16, 49.	1.2	7
64	Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics. Endocrinology and Metabolism, 2017, 32, 36.	1.3	11
65	The Impact of Diabetes Mellitus on Vascular Biomarkers in Patients with End-Stage Renal Disease. Yonsei Medical Journal, 2017, 58, 75.	0.9	8
66	Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels. PLoS ONE, 2017, 12, e0186446.	1.1	13
67	Characteristics and Vascular Complications of Familial Hypercholesterolemia in Korea. Journal of Atherosclerosis and Thrombosis, 2016, 23, 532-538.	0.9	6
68	The Effect of FLT1 Variant on Long-Term Cardiovascular Outcomes: Validation of a Locus Identified in a Previous Genome-Wide Association Study. PLoS ONE, 2016, 11, e0164705.	1.1	0
69	Statin Intensity and Clinical Outcome in Patients with Stable Coronary Artery Disease and Very Low LDL-Cholesterol. PLoS ONE, 2016, 11, e0166246.	1.1	9
70	Fixed-dose combination therapy for cardiovascular prevention. Journal of the Korean Medical Association, 2016, 59, 883.	0.1	0
71	Circulating Anti-Elastin Antibody Levels and Arterial Disease Characteristics: Associations with Arterial Stiffness and Atherosclerosis. Yonsei Medical Journal, 2015, 56, 1545.	0.9	3
72	Combination pharmacotherapy in lipid management. Journal of the Korean Medical Association, 2015, 58, 745.	0.1	0

#	ARTICLE	IF	CITATIONS
73	Additive Beneficial Effects of Valsartan Combined with Rosuvastatin in the Treatment of Hypercholesterolemic Hypertensive Patients. Korean Circulation Journal, 2015, 45, 225.	0.7	23
74	Genetic Testing of Korean Familial Hypercholesterolemia Using Whole-Exome Sequencing. PLoS ONE, 2015, 10, e0126706.	1.1	24
75	Alteration in Metabolic Signature and Lipid Metabolism in Patients with Angina Pectoris and Myocardial Infarction. PLoS ONE, 2015, 10, e0135228.	1.1	83
76	Insulin Protects Cardiac Myocytes from Doxorubicin Toxicity by Sp1-Mediated Transactivation of Survivin. PLoS ONE, 2015, 10, e0135438.	1.1	40
77	Left atrial volume index is an independent predictor of hypertensive response to exercise in patients with hypertension. Hypertension Research, 2015, 38, 137-142.	1.5	11
78	Evaluation of polygenic cause in Korean patients with familial hypercholesterolemia â€" A study supported by Korean Society of Lipidology and Atherosclerosis. Atherosclerosis, 2015, 242, 8-12.	0.4	10
79	PPARÎ± agonists inhibit inflammatory activation of macrophages through upregulation of Î²-defensin 1. Atherosclerosis, 2015, 240, 389-397.	0.4	21
80	Irisin, a novel myokine is an independent predictor for sarcopenia and carotid atherosclerosis in dialysis patients. Atherosclerosis, 2015, 242, 476-482.	0.4	75
81	LC/MS-based polar metabolite profiling reveals gender differences in serum from patients with myocardial infarction. Journal of Pharmaceutical and Biomedical Analysis, 2015, 115, 475-486.	1.4	15
82	Clinical features of familial hypercholesterolemia in Korea: Predictors of pathogenic mutations and coronary artery disease â€" A study supported by the Korean Society of Lipidology and Atherosclerosis. Atherosclerosis, 2015, 243, 53-58.	0.4	42
83	Update on the Pharmacologic Agents for Dyslipidemia. Journal of Korean Diabetes, 2015, 16, 269.	0.1	0
84	C-Reactive Protein Inhibits Survivin Expression via Akt/mTOR Pathway Downregulation by PTEN Expression in Cardiac Myocytes. PLoS ONE, 2014, 9, e98113.	1.1	14
85	Red Cell Distribution Width as an Independent Predictor of Exercise Intolerance and Ventilatory Inefficiency in Patients with Chronic Heart Failure. Yonsei Medical Journal, 2014, 55, 635.	0.9	6
86	Detailed pathologic evaluation on endomyocardial biopsy provides long-term prognostic information in patients with acute myocarditis. Cardiovascular Pathology, 2014, 23, 139-144.	0.7	18
87	Comparison of association of glomerular filtration rate with metabolic syndrome in a community-based population using the CKD-EPI and MDRD study equations. Clinica Chimica Acta, 2014, 429, 157-162.	0.5	7
88	Comparison of pooled cohort risk equations and Framingham risk score for metabolic syndrome in a Korean community-based population. International Journal of Cardiology, 2014, 176, 1154-1155.	0.8	6
89	Adiponectin and progression of arterial stiffness in hypertensive patients. International Journal of Cardiology, 2013, 163, 316-319.	0.8	42
90	Association between <i>CDH13</i> Variants and Cardiometabolic and Vascular Phenotypes in a Korean Population. Yonsei Medical Journal, 2013, 54, 1305.	0.9	11

#	Article	IF	Citations
91	Response to Letter on "Effect of Atorvastatin Monotherapy and Low-Dose Atorvastatin/Ezetimibe Combination on Fasting and Postprandial Triglycerides in Combined Hyperlipedemia" Journal of Cardiovascular Pharmacology and Therapeutics, 2012, 17, 428-428.	1.0	0
92	Effect of Atorvastatin Monotherapy and Low-Dose Atorvastatin/Ezetimibe Combination on Fasting and Postprandial Triglycerides in Combined Hyperlipedemia. Journal of Cardiovascular Pharmacology and Therapeutics, 2012, 17, 65-71.	1.0	21
93	Non-lipid effects of rosuvastatin–fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia. Atherosclerosis, 2012, 221, 169-175.	0.4	14
94	Palmitate Promotes the Paracrine Effects of Macrophages on Vascular Smooth Muscle Cells: The Role of Bone Morphogenetic Proteins. PLoS ONE, 2012, 7, e29100.	1.1	21
95	The Effects of Statin Monotherapy and Low-Dose Statin/Ezetimibe on Lipoprotein-Associated Phospholipase A$_2$. Clinical Cardiology, 2011, 34, 108-112.	0.7	18
96	Effects of Atorvastatin 20 mg, Rosuvastatin 10 mg, and Atorvastatin/Ezetimibe 5 mg/5 mg on Lipoproteins and Glucose Metabolism. Journal of Cardiovascular Pharmacology and Therapeutics, 2010, 15, 167-174.	1.0	35
97	Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: Randomized comparison of fenofibrate 160mg and niacin 1500mg. Atherosclerosis, 2010, 213, 235-240.	0.4	21
98	Visceral adiposity and the severity of coronary artery disease in middle-aged subjects with normal waist circumference and its relation with lipocalin-2 and MCP-1. Atherosclerosis, 2010, 213, 592-597.	0.4	52
99	Personalized Medicine in Coronary Artery Disease: Insights From Genomic Research. Korean Circulation Journal, 2009, 39, 129.	0.7	3
100	Plasma adiponectin and resistin levels as predictors of mortality in patients with acute myocardial infarction: data from infarction prognosis study registry. Coronary Artery Disease, 2009, 20, 33-39.	0.3	52
101	Blood Eicosapentaenoic Acid and Docosahexaenoic Acid as Predictors of All-Cause Mortality in Patients With Acute Myocardial Infarction Data From Infarction Prognosis Study (IPS) Registry. Circulation Journal, 2009, 73, 2250-2257.	0.7	37
102	Tissue Doppler index, E/E', and ischemic stroke in patients with atrial fibrillation and preserved left ventricular ejection fraction. Journal of the Neurological Sciences, 2008, 271, 148-152.	0.3	47
103	Effects of Atrial Fibrillation on Arterial Stiffness in Patients With Hypertension. Angiology, 2008, 59, 459-463.	0.8	26
104	The Effects of Different β-Blockers on Left-Ventricular Volume and Function After Primary Coronary Stenting in Acute Myocardial Infarction. Angiology, 2008, 59, 676-681.	0.8	7